Nanhua Bio Medicine Co Ltd
Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protection. The Biomedicine segment engages in the provision of stem cell, immune cell storage and technical services, and medical device trade. The Energy Saving and Environmental Protection segment is involved in the external energy management … Read more
Nanhua Bio Medicine Co Ltd (000504) - Net Assets
Latest net assets as of September 2025: CN¥362.66 Million CNY
Based on the latest financial reports, Nanhua Bio Medicine Co Ltd (000504) has net assets worth CN¥362.66 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥841.96 Million) and total liabilities (CN¥479.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥362.66 Million |
| % of Total Assets | 43.07% |
| Annual Growth Rate | 13.12% |
| 5-Year Change | 109.69% |
| 10-Year Change | N/A |
| Growth Volatility | 267.18 |
Nanhua Bio Medicine Co Ltd - Net Assets Trend (1989–2024)
This chart illustrates how Nanhua Bio Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nanhua Bio Medicine Co Ltd (1989–2024)
The table below shows the annual net assets of Nanhua Bio Medicine Co Ltd from 1989 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥282.00 Million | -7.44% |
| 2023-12-31 | CN¥304.67 Million | +281.39% |
| 2022-12-31 | CN¥79.88 Million | -27.59% |
| 2021-12-31 | CN¥110.32 Million | -17.97% |
| 2020-12-31 | CN¥134.48 Million | +17.50% |
| 2019-12-31 | CN¥114.46 Million | +6.22% |
| 2018-12-31 | CN¥107.75 Million | -16.10% |
| 2017-12-31 | CN¥128.43 Million | +61.03% |
| 2016-12-31 | CN¥79.76 Million | +649.85% |
| 2015-12-31 | CN¥-14.51 Million | -306.42% |
| 2014-12-31 | CN¥7.03 Million | +96.81% |
| 2013-12-31 | CN¥3.57 Million | +117.16% |
| 2012-12-31 | CN¥-20.80 Million | -115.96% |
| 2011-12-31 | CN¥130.38 Million | -19.09% |
| 2010-12-31 | CN¥161.13 Million | +11.67% |
| 2009-12-31 | CN¥144.30 Million | -48.12% |
| 2008-12-31 | CN¥278.16 Million | -38.05% |
| 2007-12-31 | CN¥449.00 Million | +1.18% |
| 2006-12-31 | CN¥443.78 Million | -0.47% |
| 2005-12-31 | CN¥445.86 Million | +0.45% |
| 2004-12-31 | CN¥443.86 Million | +4.81% |
| 2003-12-31 | CN¥423.50 Million | +9.35% |
| 2002-12-31 | CN¥387.30 Million | +20.17% |
| 2001-12-31 | CN¥322.29 Million | -16.45% |
| 2000-12-31 | CN¥385.75 Million | +122.30% |
| 1999-12-31 | CN¥173.52 Million | -50.80% |
| 1998-12-31 | CN¥352.69 Million | -36.01% |
| 1997-12-31 | CN¥551.14 Million | +1.86% |
| 1996-12-31 | CN¥541.09 Million | -13.31% |
| 1995-12-31 | CN¥624.18 Million | +3.01% |
| 1994-12-31 | CN¥605.96 Million | +9.46% |
| 1993-12-31 | CN¥553.60 Million | +217.54% |
| 1992-12-31 | CN¥174.34 Million | +57.72% |
| 1991-12-31 | CN¥110.54 Million | +86.52% |
| 1990-12-31 | CN¥59.26 Million | +1471.98% |
| 1989-12-31 | CN¥3.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nanhua Bio Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 55094652200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥330.02 Million | 139.19% |
| Other Comprehensive Income | CN¥44.70 Million | 18.85% |
| Other Components | CN¥413.32 Million | 174.33% |
| Total Equity | CN¥237.10 Million | 100.00% |
Nanhua Bio Medicine Co Ltd Competitors by Market Cap
The table below lists competitors of Nanhua Bio Medicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhong Fu Tong Co Ltd
SHE:300560
|
$288.57 Million |
|
Infinity Natural Resources, Inc.
NYSE:INR
|
$288.61 Million |
|
Robostar Co.Ltd
KQ:090360
|
$288.71 Million |
|
Stendörren Fastigheter AB (publ)
ST:STEF-B
|
$288.80 Million |
|
HOSHF
PINK:HOSHF
|
$288.34 Million |
|
Huali Industries
SHG:603038
|
$288.34 Million |
|
Ponce Financial Group Inc
NASDAQ:PDLB
|
$288.24 Million |
|
Hap Seng Consolidated Bhd
KLSE:3034
|
$288.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanhua Bio Medicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 256,941,198 to 237,095,180, a change of -19,846,018 (-7.7%).
- Net loss of 19,846,018 reduced equity.
- Dividend payments of 931,456 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-19.85 Million | -8.37% |
| Dividends Paid | CN¥931.46K | -0.39% |
| Other Changes | CN¥931.46K | +0.39% |
| Total Change | CN¥- | -7.72% |
Book Value vs Market Value Analysis
This analysis compares Nanhua Bio Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 18.39x to 14.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1992-12-31 | CN¥0.56 | CN¥10.31 | x |
| 1993-12-31 | CN¥1.78 | CN¥10.31 | x |
| 1994-12-31 | CN¥1.95 | CN¥10.31 | x |
| 1995-12-31 | CN¥2.01 | CN¥10.31 | x |
| 1996-12-31 | CN¥1.70 | CN¥10.31 | x |
| 1997-12-31 | CN¥1.73 | CN¥10.31 | x |
| 1998-12-31 | CN¥1.09 | CN¥10.31 | x |
| 1999-12-31 | CN¥0.52 | CN¥10.31 | x |
| 2000-12-31 | CN¥1.01 | CN¥10.31 | x |
| 2001-12-31 | CN¥1.04 | CN¥10.31 | x |
| 2002-12-31 | CN¥1.25 | CN¥10.31 | x |
| 2003-12-31 | CN¥1.35 | CN¥10.31 | x |
| 2004-12-31 | CN¥1.41 | CN¥10.31 | x |
| 2005-12-31 | CN¥1.42 | CN¥10.31 | x |
| 2006-12-31 | CN¥1.42 | CN¥10.31 | x |
| 2007-12-31 | CN¥1.43 | CN¥10.31 | x |
| 2008-12-31 | CN¥0.90 | CN¥10.31 | x |
| 2009-12-31 | CN¥0.46 | CN¥10.31 | x |
| 2010-12-31 | CN¥0.48 | CN¥10.31 | x |
| 2011-12-31 | CN¥0.42 | CN¥10.31 | x |
| 2012-12-31 | CN¥-0.07 | CN¥10.31 | x |
| 2013-12-31 | CN¥0.00 | CN¥10.31 | x |
| 2014-12-31 | CN¥0.01 | CN¥10.31 | x |
| 2015-12-31 | CN¥-0.05 | CN¥10.31 | x |
| 2016-12-31 | CN¥0.02 | CN¥10.31 | x |
| 2017-12-31 | CN¥0.08 | CN¥10.31 | x |
| 2018-12-31 | CN¥-0.03 | CN¥10.31 | x |
| 2019-12-31 | CN¥0.06 | CN¥10.31 | x |
| 2020-12-31 | CN¥0.09 | CN¥10.31 | x |
| 2021-12-31 | CN¥0.05 | CN¥10.31 | x |
| 2022-12-31 | CN¥0.04 | CN¥10.31 | x |
| 2023-12-31 | CN¥0.82 | CN¥10.31 | x |
| 2024-12-31 | CN¥0.72 | CN¥10.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanhua Bio Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.76%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 2.57x
- Recent ROE (-8.37%) is below the historical average (16.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1992 | 36.11% | 35.64% | 0.39x | 2.61x | CN¥45.52 Million |
| 1993 | 23.26% | 40.26% | 0.41x | 1.41x | CN¥73.44 Million |
| 1994 | 9.30% | 40.56% | 0.17x | 1.37x | CN¥-4.25 Million |
| 1995 | -1.46% | -18.85% | 0.06x | 1.38x | CN¥-71.53 Million |
| 1996 | -18.39% | 0.00% | -0.13x | 1.45x | CN¥-149.68 Million |
| 1997 | 1.93% | 6.11% | 0.23x | 1.38x | CN¥-43.38 Million |
| 1998 | -55.76% | 0.00% | -0.08x | 1.86x | CN¥-223.65 Million |
| 1999 | -34.99% | 0.00% | -0.06x | 2.96x | CN¥-72.80 Million |
| 2000 | 8.97% | 130.99% | 0.04x | 1.90x | CN¥-3.24 Million |
| 2001 | 1.58% | 2.91% | 0.29x | 1.86x | CN¥-27.14 Million |
| 2002 | 7.50% | 11.64% | 0.40x | 1.60x | CN¥-9.69 Million |
| 2003 | 7.60% | 12.45% | 0.43x | 1.42x | CN¥-10.06 Million |
| 2004 | 6.78% | 10.89% | 0.45x | 1.37x | CN¥-14.16 Million |
| 2005 | 0.47% | 0.92% | 0.34x | 1.47x | CN¥-42.11 Million |
| 2006 | 0.50% | 0.98% | 0.36x | 1.44x | CN¥-42.15 Million |
| 2007 | 0.82% | 1.15% | 0.47x | 1.52x | CN¥-41.23 Million |
| 2008 | -61.14% | -86.13% | 0.37x | 1.93x | CN¥-197.88 Million |
| 2009 | -94.43% | -75.52% | 0.43x | 2.89x | CN¥-148.92 Million |
| 2010 | 4.14% | 4.25% | 0.53x | 1.84x | CN¥-9.16 Million |
| 2011 | -23.68% | -32.90% | 0.33x | 2.19x | CN¥-42.53 Million |
| 2012 | 0.00% | -194.27% | 1.01x | 0.00x | CN¥-146.93 Million |
| 2013 | 1307.97% | 52.52% | 0.21x | 119.31x | CN¥13.70 Million |
| 2014 | -555.30% | -142.34% | 0.17x | 22.64x | CN¥-26.62 Million |
| 2015 | 0.00% | -158.65% | 0.11x | 0.00x | CN¥-19.57 Million |
| 2016 | 412.63% | 32.35% | 0.22x | 57.12x | CN¥21.23 Million |
| 2017 | -150.63% | -55.08% | 0.17x | 16.43x | CN¥-39.58 Million |
| 2018 | 0.00% | -36.89% | 0.28x | 0.00x | CN¥-34.16 Million |
| 2019 | 102.13% | 14.02% | 0.50x | 14.57x | CN¥16.96 Million |
| 2020 | 55.09% | 8.34% | 0.32x | 20.93x | CN¥11.98 Million |
| 2021 | -198.92% | -21.13% | 0.24x | 39.62x | CN¥-34.77 Million |
| 2022 | -216.11% | -14.86% | 0.36x | 40.16x | CN¥-31.14 Million |
| 2023 | -10.96% | -20.60% | 0.18x | 3.00x | CN¥-53.87 Million |
| 2024 | -8.37% | -14.76% | 0.22x | 2.57x | CN¥-43.56 Million |
Industry Comparison
This section compares Nanhua Bio Medicine Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,139,862,295
- Average return on equity (ROE) among peers: 11.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanhua Bio Medicine Co Ltd (000504) | CN¥362.66 Million | 36.11% | 1.32x | $288.51 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |